Endovastec(SH:688016) Shang Hai Zheng Quan Bao·2025-10-10 19:05Group 1 - The company has approved a second phase of share repurchase plan, intending to buy back part of its issued A-shares using its own and/or self-raised funds, with a maximum repurchase price of RMB 180 per share and a total repurchase amount between RMB 100 million and RMB 200 million [2][9] - The repurchase period is set for 12 months from the board's approval date, and the shares will be used for employee stock ownership plans or equity incentives [2][9] - The maximum repurchase price has been adjusted to RMB 178.35 per share effective from November 8, 2024, and further adjusted to RMB 178.01 per share effective from June 6, 2025, due to the implementation of profit distribution [3][10] Group 2 - As of September 2025, the company has repurchased a total of 1,263,043 shares, accounting for 0.03% of the total share capital, with a total expenditure of approximately RMB 132.75 million [4] - The highest transaction price during the repurchase was RMB 120.00 per share, while the lowest was RMB 84.26 per share [4] - The company will continue to make repurchase decisions based on market conditions and will fulfill its information disclosure obligations in a timely manner [7][15] Group 3 - The company has announced a cash dividend of RMB 1.3 per share for the 2025 semi-annual profit distribution, with the total number of shares participating in the distribution adjusted to 120,911,974 shares after excluding the repurchased shares [18][21] - The dividend distribution plan was approved during the annual general meeting held on April 18, 2025, and further reviewed by the board on August 26, 2025 [18][19] - The company will not distribute dividends to shares held in the repurchase special account, and the cash dividend will be distributed through the China Securities Depository and Clearing Corporation [19][24]